That was my initial impression, also, Yooo. But it requires a little more reading of the PR.
"About Lenzilumab
Lenzilumab is a proprietary Humaneered® first-in-class monoclonal antibody that has been proven to neutralize GM-CSF, a cytokine of critical importance in the hyperinflammatory cascade, sometimes referred to as cytokine release syndrome, or cytokine storm, associated with COVID-19 and other indications. Lenzilumab binds to and neutralizes GM-CSF, consequently improving outcomes for patients hospitalized with COVID-19..."
In the Credit Suisse interview, we have the following.
12:04 minute mark. (abbreviated comments) Tiago Fauth: What is your long term view of the Covid opportunity for Humanigen...?
Durrant: We don't know what the efficacy of the vaccines is going to be to for the inevitable new variants. And that's before we even get into the notion of stockpiling.
(Ken, I am not linking Humanigen's website because there seems to a problem with the link.
www.ir.humanigen.com "This site can’t be reached Check if there is a typo in www.ir.humanigen.com.")
What I was curious about is why, at this time, would Humanigen spend money to support the IMPACT trial?
"The study is partially funded by IMPACT with Humanigen providing lenzilumab and the remaining funding for the study."
Where's the money coming from? I have to think that the company has received stockpiling orders, alluded to above in answer to Fauth's question about the Covid opportunity for lenz, even ahead of regulatory approval (which we've seen happen with another Covid product).
News 
Market Data 
Discover 
AI
